A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
Not Applicable
Not yet recruiting
- Conditions
- Immunoglobulin G4 Related Disease
- Interventions
- Registration Number
- NCT07190196
- Lead Sponsor
- Sanofi
- Brief Summary
This is a Phase 3, parallel group, 2-arm, randomized, double blind, placebo-controlled, 52-week treatment study to assess the efficacy and safety of rilzabrutinib as a treatment for adult patients with active IgG4-RD.
The purpose of this study is to measure time to IgG4-RD clinical disease flare, and other relevant efficacy endpoints including flare-free rate, control of IgG4-RD disease activity, use of GC rescue and safety parameters such as treatment-emergent adverse events, clinical laboratory values and electrocardiograms (ECG) in participants aged 18 years and above, diagnosed with IgG4-RD and treated with rilzabrutinib tablets over a 52-week placebo-controlled period.
Study details include:
The study duration will be up to 60 weeks, including a 4-6-week screening period, a 52-week double blind treatment period, and 2 weeks of follow up (plus an optional OLE of 108 weeks).
The number of visits will be 16 (plus an optional 9 visits during the OLE).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 124
Inclusion Criteria
- Participants must have an adjudicated clinical diagnosis of IgG4-RD
- Participants meeting Step 1 Entry criteria of 2019 ACR/EULAR classification criteria for IgG4-RD and Total inclusion points are ≥20
- Participants with active disease at screening in at least one organ system, excluding lymph nodes, as an IgG4-RD Responder Index total activity score ≥ 2
- Participants with history or current involvement of at least 1 organ/site (excluding lymph nodes) affected with IgG4-RD.
- Participants with active IgG4-RD controlled for at least 2 weeks while on a stable dose of GC.
- Participants willing to taper off GC after starting IMP.
- Participants willing and able to participate in repeated study protocol mandated or clinically indicated imaging procedures to assess IgG4-RD such as computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), or ultrasound.
- Participants who have an up-to-date vaccination status as per local guidelines. The last dose of live vaccines should be received at least 30 days before Day 1.
- Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Exclusion Criteria
- Meet any Step 2 Exclusion criteria from the 2019 ACR/EULAR classification criteria for IgG4-RD.
- History of retroperitoneal fibrosis, sclerosing mesenteritis, fibrosing mediastinitis, or other overwhelmingly fibrotic expression of IgG4-RD that is the sole disease manifestation.
- Active malignancy or history of malignancy within 5 years before Day 1, except completely treated in situ carcinoma of the cervix, completely treated, and resolved nonmetastatic squamous or basal cell carcinoma of the skin.
- Known or suspected immunodeficiency, including history of invasive opportunistic infections (eg, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, and aspergillosis) despite infection resolution, or otherwise recurrent infections of abnormal frequency or prolonged duration suggesting an immune compromised status, as judged by the Investigator.
- History of serious infections with the potential for recurrence (as judged by the Investigator), with less than 4 weeks interval between resolution of serious infection and first dose of study drug, or currently active moderate to severe infection at Screening (Grade 2 or higher).
- Current or chronic history of liver disease unrelated to IgG4-RD.
- Refractory nausea and vomiting, malabsorption, external biliary shunt, bariatric surgery, or significant bowel resection that would preclude adequate rilzabrutinib/placebo absorption.
- History of solid organ transplant.
- Planned major surgical procedure during the participation in this study.
- History of drug abuse within the previous 12 months.
- Alcoholism or excessive alcohol use, defined as regular consumption of more than approximately 3 standard drinks per day.
- Prior participation in any rilzabrutinib studies or other BTK inhibitor studies.
- History of treatment with an investigational drug within 6 months or 5 half-lives of the investigational drug, whichever is longer.
- Laboratory abnormalities at the screening visit identified by the central laboratory The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Rilzabrutinib Rilzabrutinib Rilzabrutinib Rilzabrutinib Glucocorticoid Rilzabrutinib Placebo Glucocorticoid Placebo Placebo Placebo Placebo
- Primary Outcome Measures
Name Time Method Time to first adjudicated clinical disease flare treated by the investigator during the Blinded Treatment period Until Week 52 The Adjudication Committee will include internationally recognized independent experts in diagnosis and management of patients with IgG4-RD, blinded to participant, investigator, and site identifiers
- Secondary Outcome Measures
Name Time Method Percentage of participants without IgG4-RD adjudicated clinical disease flare and off glucocorticoids and immunomodulators At Week 52 Percentage of participants without IgG4-RD adjudicated clinical disease flare and off glucocorticoids At Week 52 Annualized rate of clinical disease flares At Week 52 Percent change in IgG4-RD RI total activity scores From baseline to Week 12 Change in IgG4-RD RI total activity scores From baseline to Week 52 Proportion of participants with reduction of ≥2 points from the baseline IgG4-RD RI total activity score At Week 12, Week 24, and Week 52 Cumulative glucocorticoid dose for treatment of IgG4-RD At Week 52 Proportion of participants with potentially clinically significant abnormalities in laboratory tests, vital signs, and electrocardiograms in the Safety Population Until Week 160 Proportion of participants in complete remission among participants without IgG4-RD adjudicated disease flare and off GC and immunomodulators At Week 52 Proportion of participants with TEAEs, AESIs, SAEs in the Safety Population Until Week 160